794 related articles for article (PubMed ID: 24795200)
21. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
22. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Forns X; Poordad F; Pedrosa M; Berenguer M; Wedemeyer H; Ferenci P; Shiffman ML; Fried MW; Lovell S; Trinh R; Lopez-Talavera JC; Everson G
Liver Int; 2015 Nov; 35(11):2358-62. PubMed ID: 26248955
[TBL] [Abstract][Full Text] [Related]
23. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
Smith MA; Lim A
Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
[TBL] [Abstract][Full Text] [Related]
24. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
[TBL] [Abstract][Full Text] [Related]
26. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
[TBL] [Abstract][Full Text] [Related]
27. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
Poordad F; Agarwal K; Younes Z; Cohen D; Xie W; Podsadecki T
Clin Infect Dis; 2015 Feb; 60(4):608-10. PubMed ID: 25365973
[TBL] [Abstract][Full Text] [Related]
28. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ;
Int J Drug Policy; 2018 Dec; 62():94-103. PubMed ID: 30384028
[TBL] [Abstract][Full Text] [Related]
29. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Deutsch L; Houri I; Ben-Ari Z; Shlomai A; Veitsman E; Cohen-Ezra O; Issachar A; Mor O; Gozlan Y; Bruck R; Menachem Y; Zelber-Sagi S; Katchman H; Shibolet O
BMC Infect Dis; 2020 Apr; 20(1):264. PubMed ID: 32245397
[TBL] [Abstract][Full Text] [Related]
30. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
[TBL] [Abstract][Full Text] [Related]
31. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
[TBL] [Abstract][Full Text] [Related]
33. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
[TBL] [Abstract][Full Text] [Related]
34. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
35. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
[TBL] [Abstract][Full Text] [Related]
36. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients.
Fofiu C; Boeriu A; Coman F; Fofiu A; Panic N; Bulajic M; Dobru D
Ann Hepatol; 2019; 18(1):137-143. PubMed ID: 31113582
[TBL] [Abstract][Full Text] [Related]
37. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED
Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
[TBL] [Abstract][Full Text] [Related]
38. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Said M; Omar H; Soliman Z; Saad Y; Dabes H; Hamed S; ElSaeed K; ElShazly Y; ElSerafy M
Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):89-93. PubMed ID: 30791838
[TBL] [Abstract][Full Text] [Related]
39. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
40. A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Bacinschi X; Popescu GC; Zgura A; Gales L; Rodica A; Mercan A; Serban D; Haineala B; Toma L; Iliescu L
Med Sci Monit; 2022 Jul; 28():e936706. PubMed ID: 35787600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
